ifosfamide has been researched along with Hematuria in 43 studies
Hematuria: Presence of blood in the urine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas." | 9.06 | Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. ( Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D, 1989) |
| "Twenty-five patients with progressive or recurrent neuroblastoma were treated with single-agent ifosfamide." | 9.06 | Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group. ( de Kraker, J; Hartmann, O; Ninane, J; Pritchard, J, 1987) |
| "The Gastrointestinal Tumor Study Group (GITSG) investigated the efficacy of ifosfamide with mesna uroprotection in 30 patients with advanced inoperable pancreatic carcinoma that was confirmed histologically." | 7.67 | Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group. ( , 1989) |
| "We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna." | 7.67 | The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987) |
| "This two-arm, double-blind, randomized trial was conducted to determine the effects of lenograstim, a glycosylated recombinant human granulocyte colony-stimulating factor (rHu-G-CSF), on the hematologic tolerance of patients with sarcoma treated with mesna, doxorubicin, ifosfamide, and doxorubicin (MAID) chemotherapy." | 5.08 | Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. ( Bonichon, F; Bui, BN; Chevallier, B; Chevreau, C; Cupissol, D; Fargeot, P; Krakowski, I; Maugard-Louboutin, C; Peny, AM; Thyss, A, 1995) |
| "European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas." | 5.06 | Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. ( Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D, 1989) |
| "Twenty-five patients with progressive or recurrent neuroblastoma were treated with single-agent ifosfamide." | 5.06 | Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group. ( de Kraker, J; Hartmann, O; Ninane, J; Pritchard, J, 1987) |
| " Three drugs have recently been approved: Gleevec (imatinib mesylate) at a starting dose of 400 or 600 mg daily for the treatment of malignant unresectable and/or metastatic gastrointestinal stromal tumors; Mesnex (mesna) tablets as a prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis, and Zometa (zoledronic acid) for the treatment of patients with multiple myeloma and for patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy." | 3.71 | U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. ( Cohen, MH; Dagher, R; Griebel, DJ; Ibrahim, A; Martin, A; Pazdur, R; Scher, NS; Sokol, GH; Williams, GA, 2002) |
| "The Gastrointestinal Tumor Study Group (GITSG) investigated the efficacy of ifosfamide with mesna uroprotection in 30 patients with advanced inoperable pancreatic carcinoma that was confirmed histologically." | 3.67 | Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group. ( , 1989) |
| "We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna." | 3.67 | The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987) |
| "Gemcitabine was administered at a dose of 800 mg/m2 on days 1 and 8 and ifosfamide at a dose of 2 g/m2 on days 1 and 8 with adequate amount of Mesna." | 2.70 | Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. ( Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kalofonos, H; Kiamouris, C; Nicolaides, C; Pectasides, D; Visvikis, A; Xiros, N, 2001) |
| "Ifosfamide was administered by intravenous drip infusion at a daily dose of 2 g/m2 for 5 consecutive days, and mesna was intravenously administered at 20% of the ifosfamide dose, three times daily for 5 consecutive days." | 2.67 | Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. ( Fukuoka, M; Furuse, K; Ikegami, H; Kawahara, M; Kodama, N; Masuda, N; Nakamura, S; Negoro, S; Nishio, H; Ohnoshi, T, 1991) |
| " This review summarizes dosing schedules and the incidence of hematuria in 47 clinical studies, in which oral mesna was given to at least 1,986 patients who received more than 6,475 courses of ifosfamide." | 2.39 | Oral administration of mesna with ifosfamide. ( Goren, MP, 1996) |
| "Ifosfamide dosage was reduced solely for urothelial toxicity in 11 patients receiving NAC compared with none of the patients receiving mesna (p < 0." | 1.28 | Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors. ( Einhorn, LH; Langefeld, C; Loehrer, PJ; Munshi, NC; Neuman, A; Nichols, CR; Roth, BJ; Sledge, G; Walsh, WB; Williams, SD, 1992) |
| "Hematuria was observed in 2% of the treatment cycles with the use of the antidote mercapto-ethan-sulfonate acid." | 1.27 | Ifosfamide treatment of advanced ovarian cancer. ( Arraztoa, J; Madrid, J; Wild, R; Yazigi, R, 1984) |
| "Forty-seven patients with Hodgkin's disease in relapse were treated with MIME combination chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide)." | 1.27 | MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. ( Cabanillas, F; Hagemeister, FB; McLaughlin, P; Riggs, S; Salvador, P; Tannir, N; Velasquez, WS, 1987) |
| "Ifosfamide was administered to 21 patients with recurrent or disseminated lung cancer at a dose of 4." | 1.26 | Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules. ( Costanzi, JJ; Gagliano, R; Hokanson, JA; Loukas, D; Panettiere, FJ, 1978) |
| "Ifosfamide was given in i." | 1.26 | Reduction of ifosfamide toxicity using dose fractionation. ( Bodey, GP; Freireich, EJ; McCredie, KB; McKelvey, EM; Rodriguez, V; Tashima, CK, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (67.44) | 18.7374 |
| 1990's | 10 (23.26) | 18.2507 |
| 2000's | 2 (4.65) | 29.6817 |
| 2010's | 1 (2.33) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Howe, AS | 1 |
| Pearce, J | 1 |
| Lian, F | 1 |
| Ribbons, L | 1 |
| Chumbalkar, V | 1 |
| Nazeer, T | 1 |
| Kogan, BA | 1 |
| Ramirez, MD | 1 |
| Mertens, AC | 1 |
| Esiashvili, N | 1 |
| Meacham, LR | 1 |
| Wasilewski-Masker, K | 1 |
| Cohen, MH | 3 |
| Dagher, R | 1 |
| Griebel, DJ | 1 |
| Ibrahim, A | 1 |
| Martin, A | 1 |
| Scher, NS | 1 |
| Sokol, GH | 1 |
| Williams, GA | 1 |
| Pazdur, R | 1 |
| Bryant, BM | 1 |
| Jarman, M | 1 |
| Ford, HT | 1 |
| Smith, IE | 1 |
| Harrison, EF | 4 |
| Hawke, JE | 2 |
| Hunter, HL | 4 |
| Costanzi, JJ | 4 |
| Morgan, LR | 5 |
| Plotkin, D | 2 |
| Tucker, WG | 2 |
| Worrall, PM | 2 |
| Hokanson, J | 1 |
| Mukouda, K | 1 |
| Morikawa, E | 1 |
| Hasegawa, K | 1 |
| Noumi, K | 1 |
| Ohmura, T | 1 |
| Mishima, Y | 1 |
| Kawamoto, M | 1 |
| Inagaki, A | 1 |
| Kamitsuna, A | 1 |
| Yamakido, M | 1 |
| Nishimoto, Y | 1 |
| Koyama, T | 1 |
| Katsuta, S | 1 |
| Burkert, H | 2 |
| Yazigi, R | 1 |
| Wild, R | 1 |
| Madrid, J | 1 |
| Arraztoa, J | 1 |
| Czownicki, Z | 1 |
| Utracka-Hutka, B | 1 |
| Slavik, M | 1 |
| Saiers, JH | 1 |
| Holoye, PY | 1 |
| Duelge, J | 1 |
| Hansen, RM | 1 |
| Ritch, PS | 1 |
| Anderson, T | 1 |
| Loehrer, PJ | 3 |
| Williams, SD | 3 |
| Einhorn, LH | 3 |
| Donley, PJ | 2 |
| Rodriguez, V | 2 |
| Cabanillas, F | 2 |
| Bodey, GP | 2 |
| Freireich, EJ | 2 |
| Dinçol, D | 1 |
| Içli, F | 1 |
| Karaoğuz, H | 1 |
| Cay, F | 1 |
| Arican, A | 1 |
| Demirkazik, A | 1 |
| Akbulut, H | 1 |
| Bui, BN | 1 |
| Chevallier, B | 1 |
| Chevreau, C | 1 |
| Krakowski, I | 1 |
| Peny, AM | 1 |
| Thyss, A | 1 |
| Maugard-Louboutin, C | 1 |
| Cupissol, D | 1 |
| Fargeot, P | 1 |
| Bonichon, F | 1 |
| Cassidy, J | 1 |
| Kaye, SB | 1 |
| Goren, MP | 2 |
| Shepherd, FA | 1 |
| Latreille, J | 1 |
| Paul, K | 1 |
| Eisenhauer, E | 1 |
| Pectasides, D | 1 |
| Aravantinos, G | 1 |
| Kalofonos, H | 1 |
| Kiamouris, C | 1 |
| Bafaloukos, D | 1 |
| Xiros, N | 1 |
| Nicolaides, C | 1 |
| Visvikis, A | 1 |
| Dimopoulos, MA | 1 |
| Schnitker, J | 1 |
| Fichtner, E | 1 |
| Marti, C | 1 |
| Steiner, R | 1 |
| Viollier, AF | 1 |
| Gagliano, R | 1 |
| Loukas, D | 1 |
| Panettiere, FJ | 1 |
| Hokanson, JA | 1 |
| Nelson, RL | 2 |
| Creaven, PJ | 2 |
| Fossieck, BE | 1 |
| McCredie, KB | 1 |
| McKelvey, EM | 1 |
| Tashima, CK | 1 |
| Allen, LM | 1 |
| Munshi, NC | 1 |
| Langefeld, C | 1 |
| Sledge, G | 1 |
| Nichols, CR | 1 |
| Roth, BJ | 1 |
| Neuman, A | 1 |
| Walsh, WB | 1 |
| Lokich, I | 1 |
| Anderson, N | 1 |
| Bern, M | 1 |
| Moore, C | 1 |
| Fukuoka, M | 1 |
| Negoro, S | 1 |
| Masuda, N | 1 |
| Furuse, K | 1 |
| Kawahara, M | 1 |
| Kodama, N | 1 |
| Ikegami, H | 1 |
| Nakamura, S | 1 |
| Nishio, H | 1 |
| Ohnoshi, T | 1 |
| Iwasaku-Fujimoto, M | 1 |
| Fujiwara, F | 1 |
| Todo, S | 1 |
| Morioka, Y | 1 |
| Imashuku, S | 1 |
| Munshi, N | 1 |
| Antman, KH | 1 |
| Ryan, L | 1 |
| Elias, A | 1 |
| Sherman, D | 1 |
| Grier, HE | 1 |
| Patterson, WP | 1 |
| Khojasteh, A | 1 |
| Andriole, GL | 1 |
| Sandlund, JT | 1 |
| Miser, JS | 1 |
| Arasi, V | 1 |
| Linehan, M | 1 |
| Magrath, IT | 1 |
| Pratt, CB | 1 |
| Case, DC | 1 |
| Anderson, J | 1 |
| Ervin, TJ | 1 |
| Gottlieb, A | 1 |
| Li, GC | 1 |
| Brock, N | 1 |
| Li, JQ | 1 |
| Guan, ZZ | 1 |
| He, YJ | 1 |
| de Kraker, J | 1 |
| Pritchard, J | 1 |
| Hartmann, O | 1 |
| Ninane, J | 1 |
| Hagemeister, FB | 1 |
| Tannir, N | 1 |
| McLaughlin, P | 1 |
| Salvador, P | 1 |
| Riggs, S | 1 |
| Velasquez, WS | 1 |
1 review available for ifosfamide and Hematuria
| Article | Year |
|---|---|
Oral administration of mesna with ifosfamide.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Drug Administrat | 1996 |
14 trials available for ifosfamide and Hematuria
| Article | Year |
|---|---|
Yield of Urinalysis Screening in Pediatric Cancer Survivors.
Topics: Adolescent; Adult; Child; Child, Preschool; Databases, Factual; Female; Follow-Up Studies; Glycosuri | 2016 |
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.
Topics: Acrolein; Carcinoma, Bronchogenic; Clinical Trials as Topic; Cyclophosphamide; Female; Hematuria; Hu | 1980 |
Single-dose ifosfamide: efficacy studies in non-small cell lung cancer.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cl | 1982 |
Clinical overview of mesna.
Topics: Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; Hematuria; Humans; Ifosfamide; Mercap | 1983 |
[Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
Topics: Clinical Trials as Topic; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Mercaptoethanol | 1981 |
Protective effect of N-acetylcysteine on the urotoxicity produced by oxazaphosphorine without interference with anticancer activity.
Topics: Acetylcysteine; Antineoplastic Agents; Cyclophosphamide; Hematuria; Humans; Ifosfamide; Lung Neoplas | 1982 |
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Double-Blind Met | 1995 |
Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1996 |
Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; He | 2001 |
Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724).
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Hematuria; Humans; Ifosfamide; Kidney Tubul | 1976 |
Ifosfamide continuous infusion without mesna. A phase I trial of a 14-day cycle.
Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; I | 1991 |
Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders.
Topics: Adult; Aged; Double-Blind Method; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna | 1991 |
Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Female; Hematuria; Human | 1989 |
Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group.
Topics: Bone Marrow Diseases; Child; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; Male; Neuroblas | 1987 |
28 other studies available for ifosfamide and Hematuria
| Article | Year |
|---|---|
A Case of Ewing Sarcoma of the Bladder Presenting in Early Infancy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Etopo | 2021 |
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Neoplasms; Cystitis; Diph | 2002 |
Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung.
Topics: Adenocarcinoma; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administrati | 1982 |
[Ifosfamide in the treatment of small cell carcinoma of the lung].
Topics: Adult; Aged; Carcinoma, Small Cell; Cyclophosphamide; Cystitis; Drug Administration Schedule; Drug T | 1983 |
Ifosfamide treatment of advanced ovarian cancer.
Topics: Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; Middle Aged; | 1984 |
Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria.
Topics: Acetylcysteine; Acrolein; Adenocarcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Cystitis; Dose | 1983 |
Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
Topics: Acetylcysteine; Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Dose-Response Rela | 1983 |
N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer.
Topics: Acetylcysteine; Adenocarcinoma; Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combin | 1983 |
The control of ifosfamide-induced hematuria with N-acetylcysteine in patients with advanced carcinoma of the lung.
Topics: Acetylcysteine; Administration, Oral; Cyclophosphamide; Female; Hematuria; Humans; Ifosfamide; Lung | 1982 |
Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.
Topics: Alopecia; Brain; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Hematuria; Humans; | 1982 |
Studies with ifosfamide in patients with malignant lymphoma.
Topics: Antineoplastic Agents; Bone Marrow; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; He | 1982 |
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytar | 1995 |
An unusual case of haematuria.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide | 1993 |
[Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
Topics: Adolescent; Adult; Aged; Bronchial Neoplasms; Child; Cyclophosphamide; Female; Gastrointestinal Dise | 1979 |
[High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
Topics: Adult; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Oste | 1979 |
Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules.
Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophos | 1978 |
Reduction of ifosfamide toxicity using dose fractionation.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Administration Schedule; Female; Hematuria; Humans; | 1976 |
Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724).
Topics: Alkylation; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug E | 1976 |
Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors.
Topics: Acetylcysteine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dysgerminoma; Etoposide; | 1992 |
[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
Topics: Bone Neoplasms; Child; Cyclophosphamide; Cystitis; Female; Hematuria; Humans; Ifosfamide; Leukemia; | 1990 |
Cyclophosphamide and ifosfamide: role of uroprotective agents.
Topics: Acetylcysteine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hematuria; Humans; | 1990 |
Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group.
Topics: Adult; Aged; Carcinoma; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; Male; Mesna; Nervous | 1989 |
Ifosfamide-induced renal tubular defects.
Topics: Hematuria; Humans; Hydrogen-Ion Concentration; Ifosfamide; Kidney Diseases; Kidney Tubules; Lymphoma | 1989 |
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
Topics: Adolescent; Adult; Child; Child, Preschool; Cyclophosphamide; Cystitis; Female; Hematuria; Hemorrhag | 1987 |
Ifosfamide/mesna and hematuria.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Hematuri | 1987 |
Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Evaluation; Hematologic Diseases; Hematuria; Humans | 1988 |
Ifosfamide and Mesna in advanced malignancies.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Lymphom | 1988 |
MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Hematologic Di | 1987 |